Fulgent Genetics Inc
For the period ended Mar 31, 2024. Filed May 3, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 3, 2024
FLGT$26.15+10.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except par value data)
| March 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $54,677 | $97,473 |
| Marketable securities | 251,018 | 326,681 |
| Trade accounts receivable, net of allowance for credit losses of $25,831 and $25,226 | 52,060 | 51,132 |
| Other current assets | 28,754 | 32,559 |
| Total current assets | 386,509 | 507,845 |
| Marketable securities, long-term | 540,495 | 423,571 |
| Redeemable preferred stock investment | 20,438 | 20,438 |
| Fixed assets, net | 86,723 | 83,464 |
| Intangible assets, net | 140,989 | 143,053 |
| Goodwill, net | 22,055 | 22,055 |
| Other long-term assets | 32,676 | 34,902 |
| Total assets | $1,229,885 | $1,235,328 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $19,616 | $15,360 |
| Accrued liabilities | 25,918 | 30,737 |
| Customer deposit | 27,240 | 22,700 |
| Contract liabilities | 2,762 | 2,874 |
| Notes payable, current portion | 413 | 1,183 |
| Other current liabilities | — | 164 |
| Total current liabilities | 75,949 | 73,018 |
| Deferred tax liabilities | 7,405 | 7,962 |
| Unrecognized tax benefits | 5,978 | 5,978 |
| Other long-term liabilities | 13,907 | 15,084 |
| Total liabilities | 103,239 | 102,042 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Common stock, $0.0001 par value per share, 50,000 shares authorized, 32,664 and 32,416 shares issued, respectively, and 29,890 and 29,653 shares outstanding, respectively | 3 | 3 |
| Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding | — | — |
| Additional paid-in capital | 511,329 | 501,718 |
| Accumulated other comprehensive (loss) income | (1,102) | 1,205 |
| Retained earnings | 619,713 | 633,175 |
| Total Fulgent stockholders’ equity | 1,129,943 | 1,136,101 |
| Noncontrolling interest | (3,297) | (2,815) |
| Total stockholders’ equity | 1,126,646 | 1,133,286 |
| Total liabilities and stockholders’ equity | $1,229,885 | $1,235,328 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.